Sonoma Pharmaceuticals Inc (SNOA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $5.52M
Last updated: Nov 17, 2026 at 11:01 AM ET
Sonoma Pharmaceuticals Inc (SNOA) Financials: Revenue, Profit and Cash Flow
Sonoma Pharmaceuticals reported revenue of $19.53M for the fiscal year ended Mar 31, 2026, up 36.7% from the year before. That year, net income was -$3.17M with a net margin of -16.3%, operating cash flow was -$3.93M and free cash flow was -$4.13M. The quarter ended Sep 30, 2026 had revenue of $7.17M and net income of -$66.00K.
Revenue and Margins
The operating margin was -12.6% in the fiscal year ended Mar 2026, the highest of the 9 years shown with an operating margin. Over the 9 years to Mar 2026, revenue grew from $12.82M, a compound annual rate of 4.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $19.53M | +36.7% | 38.0% | -12.6% | -16.3% |
| Mar 2025 | $14.29M | +12.2% | 38.2% | -26.0% | -24.2% |
| Mar 2024 | $12.73M | -4.0% | 37.3% | -36.9% | -38.0% |
| Mar 2023 | $13.27M | +5.1% | 33.7% | -34.4% | -38.8% |
| Mar 2022 | $12.63M | -32.2% | 31.6% | -46.6% | -40.3% |
| Mar 2021 | $18.63M | +3.9% | 35.2% | -18.5% | -21.2% |
| Mar 2020 | $17.93M | -52.7% | 45.3% | -41.2% | -18.5% |
| Mar 2019 | $37.94M | +127.8% | 46.8% | -29.7% | -31.1% |
| Mar 2018 | $16.66M | +29.9% | 43.9% | -85.2% | -86.0% |
| Mar 2017 | $12.82M | N/A | 44.2% | -101.2% | 72.3% |
Income Statement
In the fiscal year ended Mar 2026, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.53M | $14.29M | $12.73M | $13.27M | $12.63M | $18.63M | $17.93M | $37.94M | $16.66M | $12.82M |
| Cost of revenue | $12.11M | $8.82M | $7.99M | $8.79M | $8.63M | $12.07M | $9.81M | $20.18M | $9.35M | $7.16M |
| Gross profit | $7.42M | $5.46M | $4.75M | $4.48M | $3.99M | $6.56M | $8.12M | $17.76M | $7.31M | $5.67M |
| Research and development | $2.27M | $1.81M | $1.87M | $207.00K | $125.00K | $555.00K | $1.34M | $1.52M | $1.57M | $1.58M |
| Operating income | -$2.46M | -$3.71M | -$4.70M | -$4.57M | -$5.89M | -$3.45M | -$7.39M | -$11.26M | -$14.19M | -$12.97M |
| Net income | -$3.17M | -$3.46M | -$4.83M | -$5.15M | -$5.09M | -$3.95M | -$3.31M | -$11.80M | -$14.33M | $9.27M |
| EBITDA | N/A | -$2.77M | N/A | N/A | N/A | N/A | -$3.27M | -$11.04M | -$14.01M | -$12.73M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.17M | $6.41M | $5.56M | $4.35M | $5.60M | $4.01M | $3.75M | $3.56M | $3.58M | $3.39M | $3.44M | $3.14M |
| Gross profit | $2.81M | $2.58M | $2.18M | $1.65M | $2.12M | $1.46M | $1.53M | $1.27M | $1.36M | $1.31M | $1.09M | $1.46M |
| Operating income | $290.00K | -$40.00K | -$351.00K | -$678.00K | -$337.00K | -$1.09M | -$656.00K | -$1.03M | -$850.00K | -$1.17M | -$1.41M | -$844.00K |
| Net income | -$66.00K | -$330.00K | -$581.00K | -$819.00K | -$534.00K | -$1.24M | -$776.00K | -$928.00K | -$610.00K | -$1.14M | -$1.07M | -$866.00K |
Balance Sheet
As of Mar 2026, cash and equivalents exceeded short-term debt of $222.00K by $2.18M.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $13.96M | $13.69M | $14.74M | $16.23M | $18.84M | $14.99M | $14.56M | $14.45M | $19.21M | $25.46M |
| Current assets | $12.10M | $12.65M | $12.55M | $13.80M | $16.43M | $12.98M | $12.28M | $12.50M | $16.25M | $22.64M |
| Cash and equivalents | $2.40M | $5.37M | $3.13M | $3.82M | $7.40M | $4.22M | $3.69M | $3.69M | $10.07M | $17.46M |
| Total liabilities | $10.87M | $9.28M | $8.60M | $8.25M | $10.15M | $9.62M | $8.94M | $3.96M | $3.88M | $4.03M |
| Short-term debt | $222.00K | $220.00K | $323.00K | $431.00K | $808.00K | $596.00K | $481.00K | $463.00K | $377.00K | $197.00K |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $1.31M | $0 | $12.00K | $32.00K | $45.00K |
| Shareholder equity | $3.10M | $4.41M | $6.14M | $7.98M | $8.70M | $5.36M | $5.62M | $10.49M | $15.33M | $21.43M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $17.10M | $18.11M | $13.96M | $13.62M | $13.86M | $14.59M | $13.69M | $13.67M | $13.69M | $13.67M | $14.74M | $14.62M |
| Total liabilities | $10.49M | $11.51M | $10.87M | $10.19M | $10.07M | $10.54M | $9.28M | $8.80M | $8.33M | $8.70M | $8.60M | $7.93M |
| Cash and equivalents | $4.61M | $5.34M | $2.40M | $2.56M | $3.04M | $3.60M | $5.37M | $5.24M | $4.08M | $2.59M | $3.13M | $2.41M |
| Shareholder equity | $6.61M | $6.59M | $3.10M | $3.43M | $3.79M | $4.06M | $4.41M | $4.87M | $5.35M | $4.97M | $6.14M | $6.69M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Mar 2026.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.93M | -$88.00K | -$2.40M | -$6.15M | -$4.25M | -$3.38M | -$4.59M | -$11.72M | -$12.44M | -$26.64M |
| Capital expenditures | $192.00K | $80.00K | $2.00K | $269.00K | $137.00K | $179.00K | $206.00K | $100.00K | $187.00K | $394.00K |
| Free cash flow | -$4.13M | -$168.00K | -$2.40M | -$6.42M | -$4.38M | -$3.56M | -$4.80M | -$11.82M | -$12.63M | -$27.03M |
| Investing cash flow | -$192.00K | -$80.00K | -$2.00K | -$258.00K | -$99.00K | $388.00K | $3.64M | -$131.00K | -$201.00K | $18.22M |
| Financing cash flow | $477.00K | $3.03M | $1.68M | $2.49M | $7.40M | $3.31M | $1.03M | $5.49M | $5.24M | -$32.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$736.00K | -$649.00K | -$519.00K | -$764.00K | -$635.00K | -$2.02M | -$95.00K | $565.00K | $354.00K | -$912.00K | $152.00K | -$1.10M |
| Capital expenditures | $42.00K | $2.00K | $29.00K | $47.00K | $10.00K | $106.00K | $47.00K | $2.00K | $26.00K | $5.00K | $18.00K | $1.00K |
| Free cash flow | -$778.00K | -$651.00K | -$548.00K | -$811.00K | -$645.00K | -$2.12M | -$142.00K | $563.00K | $328.00K | -$917.00K | $134.00K | -$1.10M |
Frequently Asked Questions About SNOA
What is Sonoma Pharmaceuticals' annual revenue?
Sonoma Pharmaceuticals reported revenue of $19.53M for the fiscal year ended Mar 31, 2026.
How fast is Sonoma Pharmaceuticals' revenue growing?
Revenue was up 36.7% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 13.7%.
Is Sonoma Pharmaceuticals profitable?
No. Sonoma Pharmaceuticals reported net income of -$3.17M for the fiscal year ended Mar 31, 2026, with a net margin of -16.3%.
How much free cash flow does SNOA generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of -$3.93M minus capital expenditures of $192.00K produced free cash flow of -$4.13M.
How much debt does Sonoma Pharmaceuticals have?
The balance sheet dated Mar 31, 2026 reported short-term debt of $222.00K and cash and equivalents of $2.40M.
SNOA pages: Overview, Earnings, Financials, Valuation, Competitors